Proactive Investors - Run By Investors For Investors

AstraZeneca serves up a double dose of good news

It said the US regulator had granted a priority review for its new cancer treatment and told investors a phase III trial of its diabetes medication delivered impressive results
pills and syringe
The medicine appears to be working for AZ

The drug giant AstraZeneca (LON:AZN) delivered a double dose of good news.

It said the US regulator had granted a priority review for its new cancer treatment and told investors a phase III trial of its diabetes medication delivered impressive results.

READ: AstraZeneca confirms full-year guidance; CEO says results mark an important milestone

AZ said Lynparza, which it jointly developed with Merck, is being put forward as a front-line treatment for BRCA-mutated ovarian cancer.

If approved it would be the fourth indication for the tablet, which is a new form of cancer combatant called a PARP inhibitor.

Meanwhile, a final-phase clinical study showed its drug candidate Farxiga significantly reduced hospitalisation for heart failure and incidents of cardiovascular death in people assessed who had type-2 diabetes.

“These positive results are clinically relevant to the 425mln people worldwide living with diabetes, of whom those with type-2 diabetes have two-to-five times greater risk of heart failure along with an increased risk of a heart attack or stroke,” said Elisabeth Bjork, AZ’s head of cardiovascular.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use